267 related articles for article (PubMed ID: 34663432)
1. Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer.
Guo Y; Wang J; Benedict B; Yang C; van Gemert F; Ma X; Gao D; Wang H; Zhang S; Lieftink C; Beijersbergen RL; Te Riele H; Qiao X; Gao Q; Sun C; Qin W; Bernards R; Wang C
Genome Med; 2021 Oct; 13(1):166. PubMed ID: 34663432
[TBL] [Abstract][Full Text] [Related]
2. Cdc7 activates replication checkpoint by phosphorylating the Chk1-binding domain of Claspin in human cells.
Yang CC; Kato H; Shindo M; Masai H
Elife; 2019 Dec; 8():. PubMed ID: 31889509
[TBL] [Abstract][Full Text] [Related]
3. Cdc7-Dbf4-mediated phosphorylation of HSP90-S164 stabilizes HSP90-HCLK2-MRN complex to enhance ATR/ATM signaling that overcomes replication stress in cancer.
Cheng AN; Fan CC; Lo YK; Kuo CL; Wang HC; Lien IH; Lin SY; Chen CH; Jiang SS; Chang IS; Juan HF; Lyu PC; Lee AY
Sci Rep; 2017 Dec; 7(1):17024. PubMed ID: 29209046
[TBL] [Abstract][Full Text] [Related]
4. ATR Restrains DNA Synthesis and Mitotic Catastrophe in Response to CDC7 Inhibition.
Rainey MD; Bennett D; O'Dea R; Zanchetta ME; Voisin M; Seoighe C; Santocanale C
Cell Rep; 2020 Sep; 32(9):108096. PubMed ID: 32877678
[TBL] [Abstract][Full Text] [Related]
5. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
[TBL] [Abstract][Full Text] [Related]
6. Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil.
Li W; Zhao XL; Shang SQ; Shen HQ; Chen X
Curr Cancer Drug Targets; 2015; 15(3):196-204. PubMed ID: 25643258
[TBL] [Abstract][Full Text] [Related]
7. Targeting DNA Damage Response in Prostate Cancer by Inhibiting Androgen Receptor-CDC6-ATR-Chk1 Signaling.
Karanika S; Karantanos T; Li L; Wang J; Park S; Yang G; Zuo X; Song JH; Maity SN; Manyam GC; Broom B; Aparicio AM; Gallick GE; Troncoso P; Corn PG; Navone N; Zhang W; Li S; Thompson TC
Cell Rep; 2017 Feb; 18(8):1970-1981. PubMed ID: 28228262
[TBL] [Abstract][Full Text] [Related]
8. Targeting a non-oncogene addiction to the ATR/CHK1 axis for the treatment of small cell lung cancer.
Doerr F; George J; Schmitt A; Beleggia F; Rehkämper T; Hermann S; Walter V; Weber JP; Thomas RK; Wittersheim M; Büttner R; Persigehl T; Reinhardt HC
Sci Rep; 2017 Nov; 7(1):15511. PubMed ID: 29138515
[TBL] [Abstract][Full Text] [Related]
9. ATR-Chk1-APC/CCdh1-dependent stabilization of Cdc7-ASK (Dbf4) kinase is required for DNA lesion bypass under replication stress.
Yamada M; Watanabe K; Mistrik M; Vesela E; Protivankova I; Mailand N; Lee M; Masai H; Lukas J; Bartek J
Genes Dev; 2013 Nov; 27(22):2459-72. PubMed ID: 24240236
[TBL] [Abstract][Full Text] [Related]
10. ATR kinase inhibition induces unscheduled origin firing through a Cdc7-dependent association between GINS and And-1.
Moiseeva T; Hood B; Schamus S; O'Connor MJ; Conrads TP; Bakkenist CJ
Nat Commun; 2017 Nov; 8(1):1392. PubMed ID: 29123096
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
12. Enhancer of rudimentary homolog regulates DNA damage response in hepatocellular carcinoma.
Weng MT; Tung TH; Lee JH; Wei SC; Lin HL; Huang YJ; Wong JM; Luo J; Sheu JC
Sci Rep; 2015 Apr; 5():9357. PubMed ID: 25880358
[TBL] [Abstract][Full Text] [Related]
13. ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress.
Myers K; Gagou ME; Zuazua-Villar P; Rodriguez R; Meuth M
PLoS Genet; 2009 Jan; 5(1):e1000324. PubMed ID: 19119425
[TBL] [Abstract][Full Text] [Related]
14. Chk1- and claspin-dependent but ATR/ATM- and Rad17-independent DNA replication checkpoint response in HeLa cells.
Rodríguez-Bravo V; Guaita-Esteruelas S; Florensa R; Bachs O; Agell N
Cancer Res; 2006 Sep; 66(17):8672-9. PubMed ID: 16951182
[TBL] [Abstract][Full Text] [Related]
15. The BRUCE-ATR Signaling Axis Is Required for Accurate DNA Replication and Suppression of Liver Cancer Development.
Ge C; Vilfranc CL; Che L; Pandita RK; Hambarde S; Andreassen PR; Niu L; Olowokure O; Shah S; Waltz SE; Zou L; Wang J; Pandita TK; Du C
Hepatology; 2019 Jun; 69(6):2608-2622. PubMed ID: 30693543
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the ATR-CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2.
Koppenhafer SL; Goss KL; Terry WW; Gordon DJ
Mol Cancer Res; 2020 Jan; 18(1):91-104. PubMed ID: 31649026
[TBL] [Abstract][Full Text] [Related]
17. SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors.
Jo U; Murai Y; Chakka S; Chen L; Cheng K; Murai J; Saha LK; Miller Jenkins LM; Pommier Y
Proc Natl Acad Sci U S A; 2021 Feb; 118(6):. PubMed ID: 33536335
[TBL] [Abstract][Full Text] [Related]
18. Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.
Sanjiv K; Hagenkort A; Calderón-Montaño JM; Koolmeister T; Reaper PM; Mortusewicz O; Jacques SA; Kuiper RV; Schultz N; Scobie M; Charlton PA; Pollard JR; Berglund UW; Altun M; Helleday T
Cell Rep; 2016 Jan; 14(2):298-309. PubMed ID: 26748709
[TBL] [Abstract][Full Text] [Related]
19. A Genome-Wide Pooled shRNA Screen Identifies PPP2R2A as a Predictive Biomarker for the Response to ATR and CHK1 Inhibitors.
Qiu Z; Fa P; Liu T; Prasad CB; Ma S; Hong Z; Chan ER; Wang H; Li Z; He K; Wang QE; Williams TM; Yan C; Sizemore ST; Narla G; Zhang J
Cancer Res; 2020 Aug; 80(16):3305-3318. PubMed ID: 32522823
[TBL] [Abstract][Full Text] [Related]
20. Multiple DNA damage-dependent and DNA damage-independent stress responses define the outcome of ATR/Chk1 targeting in medulloblastoma cells.
Krüger K; Geist K; Stuhldreier F; Schumacher L; Blümel L; Remke M; Wesselborg S; Stork B; Klöcker N; Bormann S; Roos WP; Honnen S; Fritz G
Cancer Lett; 2018 Aug; 430():34-46. PubMed ID: 29753759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
